Nurix Therapeutics, Inc. (NRIX) Price Target Trimmed After Q3 Miss, Buy Rating Reaffirmed

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 14, H.C. Wainwright lowered its price target on Nurix Therapeutics (NASDAQ:NRIX) from $34.00 to $33.00, while reaffirming its Buy rating after the company’s Q3 2025 earnings. Nurix reported a net loss of $1.03 per share, wider than the expected $0.68, and generated $7.9 million in revenue—well below the projected $30 million. Nurix Therapeutics, Inc. (NRIX) Price Target T ...